There is a growing recognition of the importance of augmenting product- focused learning with disease-focused learning, incorporating the value of advances in real-world evidence (RWE). In LEAPS, we aim to … Read More
Advancing Healthcare through Innovation and Collaboration
NEWDIGS is an exciting and innovative approach to developing solutions for systemwide impediments to biomedical innovation and patient care. The noncompetitive, collaborative environment encourages novel and fresh ideas and interactions to … Read More
The Role of Stop-Loss Insurance and Reinsurance in Managing Performance-Based Agreements
Over the last decade, rising healthcare costs and the availability of expensive new treatment options has led to a substantial increase in the number of patients with large insurance claims. … Read More
Baking the Cake: A decision driven framework for planning fit-forpurpose evidence across stakeholders
The LEAPS methodology begins by answering two structured questions: what evidence to produce, and how to produce it, as outlined in this two-part Research Brief series: • Part I: Baking … Read More
Payer Perspectives Survey
A survey of 77 payers representing over 280 million lives, completed in April 2019, explored perspectives concerning financing challenges and management strategies associated with durable cell and gene therapies. Download … Read More
Massachusetts Pilot Disease Selection
Rheumatoid Arthritis (RA) chosen as target for LEAPS Massachusetts (MA) Pilot (RAMA) to demonstrate the feasibility and impact of a sustainable and patient-centered healthcare learning ecosystem to optimize care regimens … Read More
Patient & Caregiver Themes Survey
Patients and caregivers are key stakeholders in the development of system-wide, implementable precision financing models for durable and curative therapies. Patient and caregiver challenges are generally assumed to be primarily … Read More
Precision Financing of Durable, Potentially Curative Therapies
Pharmaceutical Executive, January 27, 2019 Trusheim, Jane Barlow Russell Teagarden Mark Gene therapies and cellular treatments create multiple financial challenges for US healthcare payers beyond price. The work of the … Read More
Precision Financing Solutions for Durable / Potentially Curative Therapies
The NEWDIGS FoCUS consortium of multiple stakeholders (payers, providers, patient advocacy organizations, pharmaceutical developers, academics and others) has been working collaboratively since 2016 to address the need for new, innovative … Read More
Incorporation of Value-Based Payment Agreements into the Calculation of Medicaid Drug Rebates
Value-Based Payment (VBP) agreements will play an important role in mitigating uncertainty in durable therapies, where it is unclear whether a large upfront payment is justified based on limited clinical … Read More